Atlas Trials

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Clinical trial NCT02223819 · COMPLETED

Trial details

NCT number
NCT02223819
Sponsor
Columbia University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Uveal Melanoma
Start date
2015-03-01
Primary completion
2019-07-03
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.